By Sriparna Roy (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant ...

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with ...

The company was studying the drug as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia, a mental health condition that affects how people think, feel and behave.

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...